Roth Capital initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a report issued on Thursday, March 8th, MarketBeat reports. The brokerage issued a buy rating and a $17.00 price objective on the biotechnology company’s stock.
Several other research firms also recently weighed in on VTVT. Northland Securities initiated coverage on shares of vTv Therapeutics in a research note on Thursday, February 8th. They issued an outperform rating and a $28.00 price target for the company. Citigroup restated an add rating on shares of vTv Therapeutics in a research report on Wednesday, November 8th. Zacks Investment Research cut shares of vTv Therapeutics from a hold rating to a sell rating in a research report on Saturday, March 3rd. Finally, Canaccord Genuity set a $15.00 price objective on shares of vTv Therapeutics and gave the company a buy rating in a research report on Thursday, December 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $16.50.
Shares of vTv Therapeutics (NASDAQ VTVT) opened at $5.48 on Thursday. The company has a debt-to-equity ratio of -0.10, a current ratio of 0.76 and a quick ratio of 0.76. The firm has a market cap of $186.04, a price-to-earnings ratio of -3.28 and a beta of 1.48. vTv Therapeutics has a one year low of $3.57 and a one year high of $8.40.
In related news, major shareholder Ronald O. Perelman purchased 50,000 shares of vTv Therapeutics stock in a transaction that occurred on Tuesday, December 26th. The shares were bought at an average price of $4.03 per share, for a total transaction of $201,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.80% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in VTVT. State Street Corp increased its position in shares of vTv Therapeutics by 2.1% during the second quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after buying an additional 1,976 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of vTv Therapeutics during the third quarter valued at about $481,000. Creative Planning purchased a new position in shares of vTv Therapeutics during the fourth quarter valued at about $114,000. Royce & Associates LP purchased a new position in shares of vTv Therapeutics during the fourth quarter valued at about $1,352,000. Finally, Millennium Management LLC purchased a new position in shares of vTv Therapeutics during the fourth quarter valued at about $377,000. Institutional investors own 11.20% of the company’s stock.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.